Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug

Aims To Address Steep Price Rise That Impairs Patient Access

Executive Summary

While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.

You may also be interested in...



US Slams Dutch IP Policy

The US embassy in the Netherlands has attacked Dutch policies on compulsory licensing and compounding. Critics have accused it of scaremongering.

US Embassy Slams Dutch Compounding Policy

The US embassy in the Netherlands has attacked Dutch policies on compounding and compulsory licensing. Critics have accused it of scaremongering.

New Dutch ‘Excessive Price’ Watchdog Targets Leadiant’s Orphan Drug

A new Dutch foundation set up to address cases of what it says are excessive drug pricing says it plans to refer Leadiant Biosciences’ CDCA product for the rare genetic disease, cerebrotendinous xanthomatosis, to the competition authorities.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel